

**VIII. 510(k) Summary****JAN 1 8 2001**

**SUBMITTER:** DePuy AcroMed, Inc.  
325 Paramount Drive  
Raynham, MA 02780

**CONTACT PERSON:** Karen F. Jurczak

**DATE PREPARED:** October 19, 2000

**CLASSIFICATION NAME:** Piston Syringe

**PROPRIETARY NAME:** Symphony Graft Delivery System

**PREDICATE DEVICES:** Interpore Inducer Bone Graft Delivery Syringe (K972842)  
Interpore Manifold with Extension Set (K982368)

**INTENDED USE:** The Symphony Graft Delivery System is indicated for the delivery of allograft, autograft, or synthetic bone graft materials to an orthopedic surgical site. In addition, it is designed to facilitate pre-mixing of bone graft materials with I.V. fluids, blood, plasma, platelet rich plasma, bone marrow or other specific blood component(s) as deemed necessary by the clinical use requirements.

**MATERIALS:** Medical grade polycarbonate resin  
Thermoplastic elastomer compound

**PERFORMANCE DATA:** The resins, from which the components of the Symphony Graft Delivery System are manufactured, meet the requirements set forth in the Tripartite Biocompatibility Guidance for Medical Devices. This Guidance includes testing requirements for Pharmacopeia XXII, Class VI as well as the FDA modified ISO 10993-1 tests for biocompatibility for human body fluid contact of 30 days or less.

The luer lock connections meet ISO 594/1 and 594/2 standards for conical fittings with 6% (Luer) taper for syringes, needles and certain other medical equipment.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

JAN 18 2001

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Mr. Frank Maas  
Regulatory Affairs Manager  
Depuy Acromed  
325 Paramount Drive  
Raynham, Massachusetts 02767

Re: K003286  
Trade Name: Symphony Graft Delivery System  
Regulatory Class: Unclassified  
Product Code: LYC  
Dated: October 19, 2000  
Received: October 20, 2000

Dear Mr. Maas:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - Mr. Frank Maas

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,

  
for Celia M. Witten, Ph.D., M.D.  
Director

Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

**IV. Indications for Use**

510(k) Number (if known): K003286


Device Name: Symphony Graft Delivery System

The Symphony Graft Delivery System is indicated for the delivery of allograft, autograft, or synthetic bone graft materials to an orthopedic surgical site. In addition, it is designed to facilitate pre-mixing of bone graft materials with I.V. fluids, blood, plasma, platelet rich plasma, bone marrow or other specific blood component(s) as deemed necessary by the clinical use requirements.

(Please do not write below this line - continue on another page if needed)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use: ☒ OR Over-The-Counter Use: ☐  
(Per 21 CFR 801.109)

  
(Division Sign-Off)  
Division of General Restorative Devices  
510(k) Number K 003286